Global Respiratory Virus Vaccines Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Respiratory Virus Vaccines Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Respiratory virus vaccines are used to prevent viruses from harming the human body. There are a variety of vaccines against pancreatitis, rubella, measles, influenza, coronavirus and other viruses. The components of the vaccine are also differentiated according to age.
Respiratory Virus Vaccines report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Respiratory Virus Vaccines market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Physician's Office and Hospitals are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Respiratory Virus Vaccines industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Respiratory Virus Vaccines key manufacturers include CSL Limited, Sanofi, AstraZeneca, Merck & Co., Inc., GlaxoSmithKline plc, Serum Institute of India Pvt. Ltd., Bharat Biotech and Sinovac Biotech Ltd., etc. CSL Limited, Sanofi, AstraZeneca are top 3 players and held % sales share in total in 2022.
Respiratory Virus Vaccines can be divided into Inactivated Vaccines, Live-attenuated Vaccines and Recombinant Vaccines,, etc. Inactivated Vaccines is the mainstream product in the market, accounting for % sales share globally in 2022.
Respiratory Virus Vaccines is widely used in various fields, such as Physician's Office, Hospitals, Clinics and Pharmacies/Stores, etc. Physician's Office provides greatest supports to the Respiratory Virus Vaccines industry development. In 2022, global % sales of Respiratory Virus Vaccines went into Physician's Office filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Respiratory Virus Vaccines market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
CSL Limited
Sanofi
AstraZeneca
Merck & Co., Inc.
GlaxoSmithKline plc
Serum Institute of India Pvt. Ltd.
Bharat Biotech
Sinovac Biotech Ltd.
Segment by Type
Inactivated Vaccines
Live-attenuated Vaccines
Recombinant Vaccines
Physician's Office
Hospitals
Clinics
Pharmacies/Stores
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Respiratory Virus Vaccines market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Respiratory Virus Vaccines, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Respiratory Virus Vaccines industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Respiratory Virus Vaccines in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Respiratory Virus Vaccines introduction, etc. Respiratory Virus Vaccines Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Respiratory Virus Vaccines market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Respiratory Virus Vaccines report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Respiratory Virus Vaccines market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Physician's Office and Hospitals are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Respiratory Virus Vaccines industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Respiratory Virus Vaccines key manufacturers include CSL Limited, Sanofi, AstraZeneca, Merck & Co., Inc., GlaxoSmithKline plc, Serum Institute of India Pvt. Ltd., Bharat Biotech and Sinovac Biotech Ltd., etc. CSL Limited, Sanofi, AstraZeneca are top 3 players and held % sales share in total in 2022.
Respiratory Virus Vaccines can be divided into Inactivated Vaccines, Live-attenuated Vaccines and Recombinant Vaccines,, etc. Inactivated Vaccines is the mainstream product in the market, accounting for % sales share globally in 2022.
Respiratory Virus Vaccines is widely used in various fields, such as Physician's Office, Hospitals, Clinics and Pharmacies/Stores, etc. Physician's Office provides greatest supports to the Respiratory Virus Vaccines industry development. In 2022, global % sales of Respiratory Virus Vaccines went into Physician's Office filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Respiratory Virus Vaccines market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
CSL Limited
Sanofi
AstraZeneca
Merck & Co., Inc.
GlaxoSmithKline plc
Serum Institute of India Pvt. Ltd.
Bharat Biotech
Sinovac Biotech Ltd.
Segment by Type
Inactivated Vaccines
Live-attenuated Vaccines
Recombinant Vaccines
Segment by Application
Physician's Office
Hospitals
Clinics
Pharmacies/Stores
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Respiratory Virus Vaccines market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Respiratory Virus Vaccines, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Respiratory Virus Vaccines industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Respiratory Virus Vaccines in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Respiratory Virus Vaccines introduction, etc. Respiratory Virus Vaccines Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Respiratory Virus Vaccines market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices